Hims & Hers’ Next Act: Verticalizing Drug Supply to Fix Margins and Risk

Hook / Thesis

Hims & Hers (HIMS) has been through a turbulent 2026: an earnings miss, margin compression and a debt-funded acquisition that spooked the market. Investors punished the stock, but the core business remains simple and addressable: direct-to-consumer telehealth that sells higher-margin therapeutics and recurring care. If Hims & Hers commits to producing at least some of its own drugs - especially GLP-1 formulations and other high-margin compounds - it can materially restore gross margins, reduce supplier risk and create a credible path to the guidance it reiterated for 2026.

We think the market is under-pricing the company’s optionality from vertical integration. That makes HIMS a tactical long here: enter at $29.00, use a hard stop at $24.00 and target $40.00 over a thesis-driven recovery period. The trade is conditional: it requires visible steps toward in-house manufacturing or exclusive supply arrangements within the next 3-6 months, or meaningful margin stabilization in sequential quarters.

What Hims & Hers Does and Why It Matters

Hims & Hers operates a telehealth consultation platform that connects consumers to care across mental health, sexual health, dermatology and primary care. The company is a DTC channel for drugs and recurring services - a model that scales when unit economics stay healthy and supply is reliable.

The market cares because HIMS sits at the intersection of two powerful secular trends: consumerization of healthcare and the surge in demand for weight-loss therapeutics. Employers signaling cuts to GLP-1 coverage in 2027 is a tailwind for companies that can seamlessly sell and ship therapies directly to patients. But the company’s recent shift away from compounded GLP-1s toward lower-margin branded products hurt gross margin and profitability. Returning to higher-margin manufacturing or exclusivity could be the fastest way to reflate margins and cash flow.

Numbers that Shape the Thesis

Those numbers highlight the situation: revenue growth exists, but margin erosion and higher spending have pushed the company into a net loss. Market cap at $6.7B and EV/sales at 3.15x price the company as a growth asset, yet the fall in gross margins and high leverage argue for a near-term operational fix rather than multiple expansion alone.

How Vertical Integration Helps — The Mechanic

• Gross margin recovery - Producing or exclusively compounding GLP-1s and other high-margin offerings cuts COGS and reduces the need to sell lower-margin branded substitutes.
• Supply control - Less reliance on third-party suppliers reduces fulfillment hiccups and privacy/legal exposure tied to partner data handling.
• Pricing power - Owning formulations allows differentiated pricing and better bundling of drugs plus telehealth subscriptions.
• Strategic optionality - Manufacturing capability supports international rollouts (Eucalyptus acquisition) and diagnostics integration, making the acquisition less of a dilution risk and more of a revenue diversification play.

Catalysts to Watch (2-5)

• Management announces pilot manufacturing or exclusive supply contracts for GLP-1 compounds - clear margin upside and credibility lift.
• Sequential improvement in gross margin in the next 1-2 quarters - a move back above ~69% would signal product mix stabilization.
• Operational integration progress on the Eucalyptus acquisition showing cross-sell or revenue synergies; any ACCRETIVE guidance updates would be a major catalyst.
• Regulatory resolution or clarification around the FTC privacy suit that limits consumer churn or litigation overhang.

Trade Plan

Actionable setup: go long HIMS at an entry of $29.00 with a stop loss at $24.00 and a target of $40.00. This is a position trade that expects either margin recovery or a strategic update to validate the move toward vertical integration.

Horizon: aim for a combo of mid-term and long-term outcomes. Specifically:

• Mid term (45 trading days) - look for an initial bounce to $34.00 if sentiment improves around margins or a positive FTC/timing resolution announcement.
• Long term (180 trading days) - target $40.00 if HIMS demonstrates sequential margin recovery and progress on in-house sourcing or exclusive supplier deals that meaningfully improve gross margin and cash flow.

Why these levels? $34.00 reflects a recovery toward the 20-50 day moving averages and a partial re-rating from an improved mix. $40.00 assumes stronger margin recovery and modest multiple expansion versus current EV/sales, putting the company closer to a normalized growth multiple given stabilized profitability.

Valuation Framing

At a market cap of roughly $6.7B and EV of about $7.46B, HIMS trades at ~3.15x EV/sales and a price-to-sales of 2.83x. Those multiples assume future growth and decent margins; they become harder to defend if gross margin remains in the mid-60s and the company keeps burning cash. Conversely, restoring margins toward the low 70s and demonstrating consistent free cash flow would justify multiple expansion and validate the $40 target.

Put simply: the stock’s current multiple requires operational stability. Vertical integration is one lever that could materially change the denominator (EBITDA) and support higher valuation.

Risks (at least 4)

• Regulatory and legal risk: The FTC complaint over alleged privacy breaches is active. A negative outcome or prolonged litigation could damage retention, increase costs, and keep multiple depressed.
• Execution risk on manufacturing: Building or integrating drug manufacturing is capital- and time-intensive. Delays or cost overruns would crush the near-term thesis.
• Balance sheet and dilution risk: The $350M zero-coupon convertible debt and other leverage from the Eucalyptus acquisition mean either dilution or cash repayment risk, hurting per-share economics if growth disappoints.
• Market and demand risk: Re-pricing of GLP-1 coverage by employers is a catalyst if it drives DTC demand; however, if payers reintroduce coverage or competition commoditizes the channel, unit economics could weaken.
• Sentiment and short interest: Elevated short interest and heavy short volume create volatility and the potential for sharp moves lower during earnings or news shocks.

Counterarguments

One reasonable counterargument: vertical integration is expensive and distracts management from core patient acquisition and product development. The company could instead focus on margin improvements via pricing, cross-sell, diagnostics upsell and tighter marketing. If management can re-optimize unit economics without heavy capex, the market may reward that route just as much as manufacturing. Also, regulatory risk around compounding and distribution of controlled substances could make in-house production more trouble than it’s worth.

Conclusion and What Would Change Our Mind

We are constructive on a tactical long in HIMS because the company has clear, actionable levers to restore margin and de-risk the business. Entry at $29.00 offers a risk-reward favoring upside if management announces an in-house supply plan or margin stabilization within a few quarters. The stop at $24.00 limits exposure to further headline-driven selling or an adverse litigation outcome, while the $40.00 target reflects a scenario of margin recovery plus multiple rerating.

What would change our view: a) confirmed management pivot away from higher-margin therapeutics toward exclusively low-margin branded products; b) another earnings miss that further compresses margins or guidance; or c) material negative judgment in the FTC matter that meaningfully reduces customer trust and retention. Conversely, a committed, funded plan to establish manufacturing capacity or exclusive supply for GLP-1s and sequential margin improvement would validate the trade and could prompt an upgrade of the target.

Trade checklist: enter at $29.00, stop $24.00, target $40.00. Watch for margin improvement, manufacturing announcements, Eucalyptus integration milestones, and updates on the FTC matter.